Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

Ben A Kappel; Michael Lehrke; Katharina Schütt; Anna Artati; Jerzy Adamski; Corinna Lebherz; Nikolaus Marx

doi:10.1161/CIRCULATIONAHA.117.029166

Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

Circulation. 2017 Sep 5;136(10):969-972. doi: 10.1161/CIRCULATIONAHA.117.029166.

Authors

Ben A Kappel¹, Michael Lehrke¹, Katharina Schütt¹, Anna Artati¹, Jerzy Adamski¹, Corinna Lebherz¹, Nikolaus Marx²

Affiliations

¹ From Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Germany (B.A.K., M.L., K.S., C.L., N.M.); Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany (A.A., J.A.); Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, Freising, Germany (J.A.); and German Center for Diabetes Research, Neuherberg, Germany (J.A.).
² From Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Germany (B.A.K., M.L., K.S., C.L., N.M.); Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany (A.A., J.A.); Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, Freising, Germany (J.A.); and German Center for Diabetes Research, Neuherberg, Germany (J.A.). [email protected].

PMID: 28874423
DOI: 10.1161/CIRCULATIONAHA.117.029166

No abstract available

Keywords: SGTL2 inhibitors; branched-chain amino acids; cardiovascular disease; empagliflozin; ketone bodies; metabolomics; type 2 diabetes mellitus.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Benzhydryl Compounds / therapeutic use*
Biomarkers / blood
Cardiovascular Diseases / blood*
Cardiovascular Diseases / diagnosis
Cardiovascular Diseases / epidemiology
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / diagnosis
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / epidemiology
Energy Metabolism / drug effects*
Female
Glucosides / therapeutic use*
Humans
Male
Metabolomics / methods
Middle Aged
Myocardium / metabolism*
Prospective Studies
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
Treatment Outcome

Substances

Benzhydryl Compounds
Biomarkers
Glucosides
Sodium-Glucose Transporter 2 Inhibitors
empagliflozin